189 related articles for article (PubMed ID: 9815898)
1. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion.
Webber MM; Waghray A; Bello D
Clin Cancer Res; 1995 Oct; 1(10):1089-94. PubMed ID: 9815898
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
3. Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion.
Ishii K; Otsuka T; Iguchi K; Usui S; Yamamoto H; Sugimura Y; Yoshikawa K; Hayward SW; Hirano K
Cancer Lett; 2004 Apr; 207(1):79-87. PubMed ID: 15050736
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A; Webber MM
Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
[TBL] [Abstract][Full Text] [Related]
5. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples.
Vukmirovic-Popovic S; Escott NG; Duivenvoorden WC
Oncol Rep; 2008 Oct; 20(4):897-903. PubMed ID: 18813833
[TBL] [Abstract][Full Text] [Related]
6. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
10. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.
Festuccia C; Giunciuglio D; Guerra F; Villanova I; Angelucci A; Manduca P; Teti A; Albini A; Bologna M
Oncol Res; 1999; 11(1):17-31. PubMed ID: 10451028
[TBL] [Abstract][Full Text] [Related]
11. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
12. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Fujiuchi Y; Nagakawa O; Murakami K; Fuse H; Saiki I
Oncol Rep; 2003; 10(4):1001-6. PubMed ID: 12792760
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.
Downing S; Bumak C; Nixdorf S; Ow K; Russell P; Jackson P
Mol Carcinog; 2003 Nov; 38(3):130-40. PubMed ID: 14587098
[TBL] [Abstract][Full Text] [Related]
14. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.
Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT
Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681
[TBL] [Abstract][Full Text] [Related]
15. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
Aalamian M; Tourkova IL; Chatta GS; Lilja H; Huland E; Huland H; Shurin GV; Shurin MR
J Urol; 2003 Nov; 170(5):2026-30. PubMed ID: 14532846
[TBL] [Abstract][Full Text] [Related]
17. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.
Zhang M; Altuwaijri S; Yeh S
Oncogene; 2004 Apr; 23(17):3080-8. PubMed ID: 15048090
[TBL] [Abstract][Full Text] [Related]
18. Aspirin inhibits highly invasive prostate cancer cells.
Lloyd FP; Slivova V; Valachovicova T; Sliva D
Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
[TBL] [Abstract][Full Text] [Related]
19. PSA affects prostate cancer cell invasion in vitro and induces an osteoblastic phenotype in bone in vivo.
Cumming AP; Hopmans SN; Vukmirović-Popović S; Duivenvoorden WC
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):286-94. PubMed ID: 21826098
[TBL] [Abstract][Full Text] [Related]
20. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
